Inactivated Sendai Virus Envelope Transfection for Neurodegenerative Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cognitive impairment and neurodegenerative diseases, such as Alzheimer-type dementia, lack effective radical solutions, and existing methods using Sendai virus (HVJ) face challenges due to high immunogenicity and cytotoxicity, limiting their therapeutic potential.
Innovation Solution
Development of an inactivated Sendai virus envelope (HVJ-E) combined with an immune checkpoint inhibitor, which enhances transfection efficiency and immunological adjuvant effects, providing a synergistic therapeutic approach for cognitive impairment and neurodegenerative diseases by improving short-term memory and reducing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If Sendai virus (HVJ) is used for transfection, then transfection efficiency is improved, but immunogenicity and cytotoxicity increase
Solution Approach 1:
The invention extracts only the essential fusogenic envelope from the Sendai virus, separating it from the viral genome and other components that cause immunogenicity and cytotoxicity. This envelope alone is sufficient to mediate cell fusion and transfection while eliminating the harmful effects of the complete virus.
Solution Approach 2:
The Sendai virus envelope acts as an intermediary carrier that mediates cell fusion and transfection without requiring the complete viral structure. It serves as a bridge between the transfection goal and the cell membrane, providing the necessary fusogenic activity while avoiding the immunogenic and cytotoxic effects of the full virus.
2Productivity
If complete Sendai virus is used, then high transfection activity is achieved, but host protein synthesis is inhibited
Solution Approach 1:
The invention removes the viral genome and replication machinery from the Sendai virus structure, retaining only the envelope that contains the fusion proteins. This extraction eliminates the ability of the virus to replicate and inhibit host protein synthesis while preserving the envelope's fusogenic transfection activity.
3Reliability
If UV inactivated HVJ is used to reduce immunogenicity, then transfection safety is improved, but transfection efficiency decreases
Solution Approach 1:
Instead of using UV inactivation that damages the envelope structure, the invention extracts the envelope in a controlled manner that preserves its fusogenic integrity. This extraction method maintains transfection efficiency while inherently providing safety by removing the viral genome and replication capacity.
Solution Approach 2:
The invention changes the preparation method from UV irradiation (which damages the envelope) to a gentle extraction process that preserves the envelope's structural integrity and fusogenic activity. This parameter change in the preparation method maintains both safety and efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of HVJ-E with an immune checkpoint inhibitor offers a synergistic effect, effectively treating cognitive impairment and neurodegenerative diseases with reduced side effects and improved therapeutic outcomes, including enhanced memory improvement in Alzheimer's disease models.
Implementation Method 1
the inventors have found that HVJ-E exhibits immunological adjuvant effect by encapsulating a chemotherapeutic agent such as an anticancer agent into HVJ-E and transfecting the HVJ-E into cells or the living body
Implementation Method 2
Sendai virus (Hemaglutinating virus of Japan (HVJ)) have attracted attention for causing fusion of Erich tumor cells. Its activity of fusing the cell membrane (hereinafter, referred to as the fusing activity) has been analyzed
Data Source
Figure 1
Figure 2A~2C
Figure 3A~3B
AI summary
The present invention relates to a medicament for preventing and/or treating cognitive impairment and/or a neurodegenerative disease with accumulation of a prionoid, comprising a Sendai virus envelope as an active ingredient and combined application of the medicament and an immune checkpoint inhibitor.